Journal of Biological and Sustainability Sciences
An International Peer-Reviewed Open Access Journal
Vol. 2 • No. 1 • 2026 | DOI: 10.5281/zenodo.23763188 | jbss.biosuss.com

REVIEW ARTICLE

Gymnema sylvestre and Gymnemic Acid in Type 2 Diabetes: A Comprehensive Evidence Review of Clinical, Mechanistic, Phytochemical, Biotechnological, and Safety Data

Muhammad Sanan[1*], Malaika Afzaal[2], Muhammad Hanan[2], Abdul Ahad[3], Muhammad Sheraz Ahmad[4]

[1] Department of Pharmacy, Faculty of Pharmacy, International Institute of Science, Art and Technology (IISAT), Gujranwala, Pakistan; Email ID: Malaika.zong@gmail.com, Hananhani759@gmail.com

[2] Department of computer science, Faculty of Pharmacy, International Institute of Science, Art and Technology (IISAT), Gujranwala, Pakistan

[3] Department of Nursing, The University of Chenab, Gujrat, Pakistan; Email ID: ahaddoga333@gmail.com

[4] Doctor of Veterinary Medicine (DVM), University of Veterinary and Animals Sciences, Lahore, Pakistan; Email ID: sa8545998@gmail.com

Corresponding author: Muhammad Sanan, Email; sanansani859@gmail.com

PUBLICATION DETAILS

Received: 2026-10-06

Revised: 2026-10-21

Accepted: 2026-10-23

Published: 2026-10-29

Article ID: JBSS-2026-0011

ABSTRACT

Background: *Gymnema sylvestre R*.Br. (Apocynaceae), commonly known as gurmar, has a long history of use in traditional medicine for dysglycemia. Its major bioactive constituents include triterpenoid saponins collectively described as gymnemic acids, gymnema saponins, and peptide constituents such as gurmarin. Interest in *Gymnema has intensified* because experimental and early clinical studies suggest effects on intestinal glucose handling, sweet-taste perception, insulin secretion, insulin sensitivity, lipid metabolism, and cellular stress pathways. Objective: To critically synthesize clinical, mechanistic, phytochemical, extraction, and safety evidence for *G. sylvestre* and gymnemic acid in type 2 diabetes mellitus (T_2DM), impaired glucose tolerance (IGT), and related metabolic disorders, while identifying the principal limitations that currently prevent firm therapeutic conclusions. Methods: A structured comprehensive evidence review was prepared using the manuscript's core clinical and mechanistic literature together with a newly supplied evidence export containing 295 bibliographic records. The export was audited for screening status, verification, duplicate titles, extractable study characteristics, and direct Gymnema/gymnemic-acid relevance. Because none of the exported records was citation- or full-text-verified and structured outcome fields were empty, the file was used for evidence discovery and reconciliation rather than as a source of uncritical pooled estimates. Directly relevant records were checked against publisher or PubMed information where available. Human intervention evidence, systematic reviews, mechanistic studies, phytochemistry, production technology, and safety data were synthesized narratively. Results: The evidence export contained 295 records representing 270 unique titles; 294 records were labelled "included" despite remaining unscreened, and all 295 had citation_verified = false and full_text_verified = false. Six records directly named Gymnema or gymnemic acid. Reconciliation confirmed clinically relevant human evidence from historical *Gymnema extracts*, a small T_2DM cohort using OSA extract, a randomized placebo-controlled trial in impaired glucose tolerance, and a 2021 meta-analysis of 10 studies (419 participants), together with mechanistic evidence for insulin secretion, intestinal glucose handling, endoplasmic-reticulum stress, insulin signalling, oxidative stress, and glycogen-regulatory pathways. The supplied dataset also added useful production and formulation evidence on gymnemic-acid extraction, cell-suspension culture, and tissue-culture approaches. Overall clinical signals are favorable but heterogeneous, and confidence remains limited by small samples, variable preparations, historical study design, and in complete standardization. Conclusion: *G. sylvestre* and gymnemic-acid-rich preparations are promising adjunctive candidates for dysglycemia, but the present evidence does not justify replacing established diabetes therapy. Future trials should use chemically standardized preparations, prespecified doses, adequate placebo control, clinically meaningful outcomes, prospective safety monitoring, and transparent reporting of concomitant medication changes.

KEYWORDS

Gymnema sylvestre; gymnemic acid; type 2 diabetes mellitus; impaired glucose tolerance; glycemic control; insulin resistance; phytotherapy; nutraceutical; systematic evidence synthesis

© 2026 The Author (s). Published in the Journal of Biological and Sustainability Sciences (JBSS), a journal of BIOSUSS Publishing (Pvt.) Limited. Authors retain copyright and grant BIOSUSS Publishing (Pvt.) Limited the non-exclusive right of first publication. This open-access article is distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). **Journal information and contact: jbss.biosuss.com**

Cite this article: Sanan M, Afzaal M, Hanan M, Ahad A, Ahmad MS. *Gymnema sylvestre* and Gymnemic Acid in Type 2 Diabetes: A Comprehensive Evidence Review of Clinical, Mechanistic, Phytochemical, Biotechnological, and Safety Data. J Biol Sustain Sci. 2026;2(1):20-29. DOI: https://doi.org/10.5281/zenodo.23763188

1. Introduction

Type 2 diabetes mellitus is characterized by chronic hyperglycemia arising from a combination of insulin resistance, progressive pancreatic beta-cell dysfunction, altered incretin biology, increased hepatic glucose output, dysregulated adipose metabolism, and other metabolic disturbances. Although modern pharmacotherapy substantially improves glycemic control and reduces complications, interest in plant-derived adjuncts remains high because of cultural use, accessibility, and the possibility that multicomponent preparations may act on several

metabolic pathways simultaneously [1]. *Gymnema sylvestre R*.Br. is a woody climbing plant distributed in parts of Asia, Africa, and Australia and has been used in Ayurvedic and other traditional systems for disorders associated with glucose metabolism. The Hindi name "gurmar," often translated as "sugar destroyer," reflects the plant's well-known ability to reduce sweet taste after oral exposure. Chemically, the leaves contain multiple triterpenoid saponins, particularly gymnemic acids and gymnema saponins, together with flavonoids, peptides, and other constituents. Gymnemic acids are not a single molecule but a family of structurally related triterpene glycosides; this chemical complexity is important because different fractions can have different biological activities [2,3].

Interest in Gymnema as an antidiabetic intervention is supported by several lines of evidence. First, clinical studies dating from the 1980s and 1990s reported improved glycemic indices during administration of leaf preparations, including the standardized GS_4 extract. Second, experimental work indicates that Gymnema-derived fractions can reduce intestinal glucose uptake and suppress sweet-taste signaling. Third, studies using isolated human islets and metabolic models suggest direct effects on insulin secretion and insulin signaling. Fourth, more recent controlled clinical research has extended the evidence to impaired glucose tolerance, a high-risk state preceding overt T_2DM [2-12].

However, the evidence base is difficult to interpret. Studies differ in plant authentication, extraction solvent, standardization, daily dose, duration, patient phenotype, background medication, and endpoint definition. Some interventions contain Gymnema as one component of a multi-herb preparation, making causal attribution difficult. In addition, much of the early clinical literature used open-label or non-randomized designs. Consequently, apparent efficacy must be separated from certainty of evidence. [13-16]

The objective of this review is therefore not merely to summarize positive findings, but to integrate clinical outcomes with mechanistic plausibility, phytochemical composition, extraction and standardization issues, safety, and the methodological limitations that must be addressed before Gymnema-derived preparations can be positioned responsibly within evidence-based diabetes care. [2,3,13-15]

2. Methods

2.1 Review design

This manuscript was prepared as a structured comprehensive evidence review with systematic elements. It emphasizes verifiable evidence relevant to *Gymnema sylvestre*, gymnemic acids, dysglycemia, insulin physiology, glucose absorption, sweet-taste signaling, and safety. It does not reproduce the original draft's numerical PRISMA flow because the source evidence audit identified extensive unverified records and missing study-level data. [17]

2.2 Review question and eligibility framework

The principal question was: *What is the clinical and mechanistic evidence that G. sylvestre or gymnemic-acid-rich preparations improve glycemic or related metabolic outcomes, and what safety and standardization issues determine their translational value?*

Table 1. Eligibility framework used for inclusion and exclusion of evidence in the review.

Domain	Included	Excluded or treated separately
Population	Adults with T_2DM, impaired glucose tolerance/prediabetes; mechanistic models relevant to diabetes	Unrelated diseases unless they contributed directly to safety or mechanism
Intervention	*G. sylvestre* leaf, standardized extracts, gymnemic-acid-rich fractions, isolated gymnemic acid	Multi-herb formulations were not used as primary proof of Gymnema-specific efficacy
Comparators	Placebo, usual care, baseline, untreated/control models	None required for mechanistic studies, but lack of comparator was treated as a limitation
Outcomes	Fasting/postprandial glucose, HbA1c, OGTT, insulin/C-peptide, insulin sensitivity, lipids, glucose uptake, safety	Outcomes unrelated to metabolic action
Study types	Randomized trials, clinical trials,	Editorials, duplicate records, decision letters,
	cohort/open-label intervention studies, systematic reviews/meta-analyses, mechanistic and safety studies	peer-review correspondence

2.3 Information sources and search concepts

The evidence set was assembled from PubMed-indexed records, NCBI resources, full-text repositories when available, publisher pages, and backward reference chaining from high-relevance reviews and meta-analyses. Core concepts included "*Gymnema sylvestre*," "gymnemic acid," "GS_4," "OSA," "type 2 diabetes," "impaired glucose tolerance,"

"glycemic control," "insulin secretion," "insulin resistance," "glucose absorption," "sweet taste," "toxicity," and "liver injury." Priority was given to primary human studies and primary mechanistic studies, with recent reviews used to identify older literature and contextualize consistency across the field. [2,3,13-15]

2.4 Data extraction and evidence appraisal

For human studies, extracted elements included population, sample size, formulation, dose, duration, comparator, primary metabolic findings, and key design limitations. Mechanistic evidence was grouped by biological pathway. Safety evidence was interpreted conservatively: absence of reported adverse events was not equated with proven safety, particularly in small or short-duration studies. Formal certainty grading was not attempted because complete reports and standardized study-level risk-of-bias information were not available for all historical studies.

2.5 Audit of the supplied evidence dataset

The supplied CSV contained 295 records from 3 source labels (Europe PMC: 100, Crossref: 99, PubMed: 96). It contained 270 unique titles, indicating 25 duplicate-title rows. Although 294 records carried an included = true flag, 294 remained unscreened. Citation verification and full-text verification were false for all 295 records. The structured fields for population, intervention, comparator, outcomes, study design, sample size, effect estimate, confidence interval, key findings, and risk-of-bias tool were empty throughout the export. Therefore, the dataset cannot by itself support a PRISMA inclusion count, risk-of-bias synthesis, or quantitative meta-analysis.

A direct title search for "Gymnema" or "gymnemic" identified 6 records. These were treated as the highest-priority records for manual reconciliation. One exported DOI for the 2019 gymnemic-acid study ended in ".s001", which denotes supporting information rather than the main article; the verified article DOI is 10.1021/acs.jafc.9b00431. The dataset also contained one record with publication year 2027, which was not used as current evidence in this manuscript.

Table 2. *Gymnema sylvestre*- and gymnemic acid-related records identified in the supplied evidence export and their use in the present review.

Record from evidence export	Year	Evidence type / relevance	Verification status in export	How used in this review
Gymnemic Acid Alleviates Type 2 Diabetes Mellitus and Suppresses Endoplasmic Reticulum Stress in Vivo and in Vitro [18]		Preclinical T_2DM + HepG2 mechanism	Not citation-verified; not full-text-verified	Verified externally; ER-stress/insulin-signalling results integrated.
Extraction and Purification of Gymnemic Acid from *Gymnema sylvestre R*.Br. [19]	2020	Extraction/purification chapter	Not citation-verified; not full-text-verified	Supports standardization and production discussion.
GTF-231, a Mixture of Gymnemic Acid, Trigonelline and Ferulic Acid Significantly Ameliorates Oxidative Stress in Experimental Type 2 Diabetes in Rats [20]	2018	Rat T_2DM combination study	Not citation-verified; not full-text-verified	Verified externally; treated as combination evidence, not *Gymnema monotherapy*.
Production of Gymnemic Acid from Cell Suspension Cultures of *Gymnema sylvestre* [21]	2016	Biotechnological production chapter	Not citation-verified; not full-text-verified	Supports cell-culture production section.
Application of different tissue culture techniques for in vitro production of gymnemic acid: factors, approaches, and challenges to achieve higher yield [22]	2024	Tissue-culture production chapter	Not citation-verified; not full-text-verified	Supports scalable production and yield-optimization discussion.
Molecular Docking Studies Involving the Inhibitory Effect of Gymnemic Acid, Trigonelline and Ferulic Acid, the Phytochemicals with Antidiabetic Properties, on Glycogen Synthase Kinase 3 (a and ß) [23]	2018	In-silico GSK-3 docking study	Not citation-verified; not full-text-verified	Verified externally; supports hypothesis-generating glycogen pathway mechanism.

3. Results

3.1 Overview of the clinical evidence

The most coherent clinical evidence concerns glycemic control in T_2DM or impaired glucose tolerance. The accompanying evidence export did not contain completed study-level extraction, so clinical effect estimates were not taken from its empty outcome fields. Instead, the direct *Gymnema records* were used to identify or cross-check relevant literature, while established clinical studies and systematic reviews were verified independently. A 2021 systematic review and meta-analysis synthesized 10 studies involving 419 participants and reported significant improvements from baseline in fasting glucose, postprandial glucose, HbA1c, triglycerides, and total cholesterol; however, heterogeneity was very high for several outcomes. This combination of favorable direction and high heterogeneity is the central feature of the current human evidence base. [13]

Table 3. Summary of the principal clinical studies and evidence syntheses evaluating *Gymnema sylvestre* in diabetes and impaired glucose tolerance.

Study	Population	Intervention	Duration	Main findings	Major limitation
[24]	Diabetic adults (small early study; *n*≈6 diabetic participants)	Leaf decoction/powdered leaves, ~6 g/day	15 days	Fasting and post-glucose glycemia decreased	Very small sample; early methods; limited modern reporting
[4]	T_2DM on oral hypoglycemic agents (*n*=22 treated)	GS_4 leaf extract, 400 mg/day	18–20 months	Reduced blood glucose, HbA1c and glycosylated plasma proteins; medication dose reduced; 5/22 discontinued conventional drug while maintaining glycemic control	Open-label/non-randomized; medication changes confound effect size; small sample
[25]	Insulin-dependent diabetes (*n*=27 treated)	GS_4, 400 mg/day	6–30 months	Reduced fasting glucose, HbA1c, insulin requirement; C-peptide/insulin-related improvements reported	Not T_2DM; non-randomized; historical trial; limited safety reporting
Al-Romaiyan et al., 2010 [5]	T_2DM (small cohort, *n*≈11)	High-molecular-weight extract OSA, 1 g/day	60 days	Lower fasting/postprandial glucose with increased insulin and C-peptide; human-islet experiments supported insulin-secretory effect	Small, non-randomized cohort; extract not equivalent to GS_4
[26]	T_2DM (*n*=58)	*G. sylvestre* supplementation, 500 mg/day	~3 months	Reductions in fasting and postprandial glucose, HbA1c and some lipid/insulin-resistance measures reported	Open-label; formulation/standardization details insufficient for cross-study dose equivalence
[27]	T_2DM (*n*=32)	GSPF kwath, a 10-herb polyherbal formulation	6 months	Reductions in blood glucose, HbA1c, total cholesterol,	Before-and-after observational study; multi-herb formulation prevents
		containing G. sylvestre; 50 mL aqueous extract derived from 10 g formulation daily		triglycerides, LDL and VLDL; HDL increased; oxidative-stress markers improved	attribution of effect to *Gymnema alone*
Gaytán Martínez et al., 2021 [6]	Impaired glucose tolerance (*n*=30; 15 active/15 placebo)	*G. sylvestre* 300 mg twice daily (600 mg/day)	12 weeks	2-h OGTT 9.1→7.8 mmol/L; HbA1c 5.8→5.4%; improved Matsuda insulin-sensitivity index; lower weight/BMI/LDL	Small RCT; prediabetes/IGT rather than established T_2DM
[13]	T_2DM systematic review/meta-analysis (10 studies; 419 participants)	Various *G. sylvestre* preparations	Variable	Pooled reductions in FBG, PPBG, HbA1c, triglycerides and total cholesterol	High heterogeneity; baseline-vs-post analyses; diverse formulations and designs

Interpretive note: The table deliberately distinguishes direct *Gymnema monotherapy*/extract studies from reports whose formulation details are less clear. This prevents a multi-herb or incompletely verified intervention from being treated as equivalent to a standardized *Gymnema preparation*.

3.2 Glycemic control

Across the clinical literature, the most consistent direction of effect is a reduction in fasting and/or postprandial glucose. The classic GS_4 study in T_2DM reported improvement in glucose and glycation measures over 18–20 months alongside reduced conventional medication requirements. Although clinically interesting, the design does not separate treatment effect from time, changes in medication, adherence, diet, or regression to the mean as effectively as a modern randomized placebo-controlled trial would. [4]

The 2021 randomized trial in impaired glucose tolerance provides stronger internal validity. Participants receiving 600 mg/day for 12 weeks had a statistically significant reduction in 2-h OGTT glucose and HbA1c, with nearly half of the active-treatment group reaching normal HbA1c values at the end of the intervention. Because this population had IGT rather than established T_2DM, the findings are most directly applicable to early dysglycemia and should not be extrapolated automatically to advanced diabetes. [6]

The meta-analysis strengthens the inference that the signal is not confined to a single historical study, but its very high heterogeneity is central to interpretation. Differences in formulation, duration, comparator, background therapy, study quality, and baseline disease severity almost certainly contribute. Consequently, the evidence supports a probable glucose-lowering signal but not a precise universal effect size for "Gymnema" as a class. [13]

3.3 Effects on insulin secretion and insulin sensitivity

A recurring mechanistic theme is enhancement of insulin secretion. In the small clinical study of OSA extract, increases in circulating insulin and C-peptide accompanied reductions in fasting and postprandial glucose. Importantly, the same investigation showed direct insulin-secretory effects in isolated human islets, reducing the gap between clinical association and biological mechanism. [5]

The randomized IGT study suggested an addition al insulin-sensitizing component: the Matsuda index increased after intervention. This is compatible with a broader metabolic action that may include reduced glucotoxicity, altered nutrient absorption, or improved insulin signaling. Preclinical work with gymnemic acid also supports effects on insulin-receptor signaling, including shifts in IRS-1 phosphorylation consistent with improved signal transduction. [6,18]

3.4 Lipid and anthropometric outcomes

Several reports describe reductions in triglycerides, total cholesterol, LDL cholesterol, body weight, or BMI. The 2021 meta-analysis found pooled reductions in triglycerides and total cholesterol, while the IGT randomized trial reported lower LDL cholesterol and modest anthropometric improvement. These findings are biologically plausible but should be considered secondary evidence because many studies were not designed primarily around lipid endpoints and heterogeneity remains substantial. [6,13]

It is also unclear whether lipid improvements reflect direct effects of *Gymnema constituents*, improved glycemia, changes in diet due to altered sweet taste, reduced energy intake, or combinations of these factors. Future trials should therefore predefine lipid and weight outcomes and measure dietary intake to help distinguish direct from behaviorally mediated effects.

3.5 Mechanistic evidence

Table 4. Proposed mechanisms of action of *Gymnema sylvestre* and gymnemic acid relevant to glucose homeostasis and metabolic regulation.

Pathway	Evidence	Clinical interpretation
Intestinal glucose uptake	Gymnemic-acid-containing fractions inhibited glucose-evoked intestinal electrical responses and reduced glucose rise in experimental tolerance tests. [9,10]	May blunt postprandial glucose entry; fraction-specific activity means "total gymnemic acid" content may not predict effect alone.
Sweet-taste suppression	Gymnemic acids and Gymnema-derived peptides interact with sweet-taste biology; recent structural work implicates T_1R_2/T_1R_3 interactions for gurmarin-like peptides. [11,12]	Could reduce perceived sweetness and sugar reward, in directly influencing intake; translation differs between rodents and humans.
Insulin secretion	OSA extract stimulated insulin secretion in human islets and increased circulating insulin/C-peptide in a small T_2DM cohort. [5,7,8]	Provides direct beta-cell mechanism but depends on extract composition and concentration.
Insulin signaling / ER stress	Gymnemic acid improved glucose uptake in insulin-resistant HepG2 cells and reduced ER-stress markers; in T_2DM rats, fasting glucose fell dose-dependently. [18]	Supports cellular insulin-sensitizing effects; animal/cell doses cannot be directly converted to human clinical doses.
Beta-cell preservation/regeneration	Historical clinical interpretations and animal studies suggest improved endogenous insulin function. [2-5,25]	Regeneration in humans is not established; the term should be used cautiously without direct morphologic or validated function al evidence.
Lipid/oxidative-inflammatory pathways	Reviews and experimental studies report antioxidant, lipid-lowering and anti-inflammatory actions. [2,3,20]	Likely extract- and model-dependent; clinical mediation remains uncertain.

3.6 Gymnemic acid: chemistry, extraction, and standardization

Gymnemic acids are a complex group of oleanane-type triterpenoid saponins rather than a single uniform active ingredient. Structural studies have identified multiple gymnemic acids, gymnemosides, and related glycosides with different acyl substitutions. Importantly, not all isolated triterpene glycosides show the same ability to inhibit glucose absorption, so a label reporting only "total gymnemic acids" may not fully characterize pharmacological potency. [2,3,9,10,19]

Extraction typically begins with authenticated *G. sylvestre* leaves followed by drying, milling, and solvent extraction. Depending on the intended fraction, aqueous, hydroalcoholic, alcoholic, and chromatographic purification steps may be used. The chapter identified in the uploaded source specifically addresses extraction and purification of gymnemic acid from *G. sylvestre*, underscoring that downstream purification is a distinct scientific problem from use of a crude leaf powder. For clinical translation, extract identity should include botanical authentication, plant part, solvent, extraction ratio, marker compounds, chromatographic fingerprint, contaminant testing, and batch-to-batch specifications. [19]

Future intervention trials should report the quantitative profile of major gymnemic acid species rather than only nominal extract mass. This would allow dose-response relationships to be compared meaningfully across studies and would reduce the present ambiguity created by using the term "*Gymnema extract*" for chemically different products.

3.7 Safety and herb–drug interaction considerations

Small clinical studies generally describe *Gymnema preparations* as well tolerated, but historical reporting of adverse events is often sparse. A formal risk-assessment review concluded that the available human and animal evidence did not show a strong general toxicity signal, while emphasizing substantial uncertainty and the potential for enhanced glucose lowering when Gymnema is combined with antidiabetic medication. [15,28]

The most clinically relevant predictable risk is excessive glucose lowering in patients already receiving insulin, sulfonylureas, or other glucose-lowering therapies, particularly if medications are adjusted without monitoring. Because some early studies intentionally reduced conventional drug doses during *Gymnema supplementation*, medication changes should be treated as a monitored clinical outcome rather than an unsupervised goal. [4,25,28]

Rare hepatotoxicity has been described. A published case report attributed acute hepatitis to *G. sylvestre* exposure, and the NCBI LiverTox assessment characterizes Gymnema as a possible rare cause of clinically apparent liver injury while noting uncertainty around attribution and product composition. This does not establish common hepatotoxicity, but it supports caution in people with pre-existing liver disease and argues for liver-safety surveillance in longer trials. [28-30]

3.8 Evidence added by the supplied dataset: biotechnological production and combination-mechanism studies

The new evidence export broadened the manuscript beyond clinical efficacy by identifying two directly relevant biotechnological production records. Nagella, Dandin and Murthy described production of gymnemic acid from *G. sylvestre* cell-suspension cultures, illustrating how controlled in-vitro culture can provide an alternative to field-grown biomass and can support reproducible metabolite production. Related experimental work optimized suspension culture conditions and reported that 10 g/L inoculum, full-strength Murashige-Skoog medium supplemented with 2.0 mg/L 2,4-D and 0.1 mg/L kinetin, and 3% (w/v) sucrose supported high biomass and a gymnemic-acid content of approximately 9.95 mg/g dry weight. A later chapter by Shahzad and colleagues reviewed tissue-culture approaches, yield determinants and challenges in increasing in-vitro gymnemic-acid production. Collectively, these records reinforce the translational importance of production platform, elicitation, culture conditions, downstream purification, and analytical stand ardization when a Gymnema-derived product is intended for clinical research. [21,22,31]

Two addition al records concerned a three-component formulation containing gymnemic acid, trigonelline and ferulic acid (GTF-231). In a high-fat-diet/low-dose-streptozotocin rat model, the 2:3:1 mixture at 300 mg/kg was reported to improve glucose homeostasis and antioxidant/oxidative-stress measures. A related molecular-docking analysis evaluated the three phytochemicals against glycogen synthase kinase-3 (GSK-3) alpha and beta; reported docking energies were hypothesis-generating rather than clinical proof. Because both studies test a combination, their effects cannot be attributed to gymnemic acid alone. They are therefore used here to illustrate plausible multitarget mechanisms and the need to distinguish isolated constituents, standardized single-herb extracts and multi-ingredient formulations. [20,23]

The 2019 study of isolated gymnemic acid provides stronger compound-specific mechanistic evidence. In insulin-resistant HepG2 cells, gymnemic acid increased glucose uptake; in T_2DM rats, 40 and 80 mg/kg/day reduced fasting blood glucose by approximately 15.2% and 26.7%, respectively. The study also reported reduced ER-stress signalling (including ORP_{150}, *p*-c-Jun, *p*-PERK and *p*-eIF2α) and a shift in IRS-1 phosphorylation consistent with improved insulin signalling. These findings strengthen biological plausibility but remain preclinical and should not be converted directly into a human dose recommendation. [18]

Table 5. Safety considerations, current evidence, and practical implications associated with *Gymnema sylvestre* and gymnemic acid use.

Safety issue	Current evidence	Practical implication
Hypoglycemia / additive glucose lowering	Biologically plausible and highlighted by risk-assessment literature when used with antidiabetic drugs [28]	Monitor glucose; medication adjustment should be clinician-directed
Gastrointestinal or non specific adverse effects	Generally uncommon in small studies; reporting quality variable [15,28]	Do not treat non-reporting as proof of absence
Hepatic injury	Rare case reports; LiverTox considers a possible rare cause [29,30]	Stop and evaluate if jaundice, marked fatigue, dark urine, or significant liver-enzyme elevation occurs
Product variability / contamination	Commercial and experimental preparations vary in composition and standardization [28]	Use authenticated, quality-controlled products with defined chemical specifications
Pregnancy, lactation, severe comorbidity	Insufficient robust evidence [28]	Avoid assuming safety in populations not studied

4. Discussion

4.1 Principal findings

The totality of evidence supports a real pharmacological signal for *G. sylvestre*, but the certainty of clinical benefit is lower than the volume of favorable mechanistic literature might imply. Human studies repeatedly point toward improved glycemia, and at least one modern randomized placebo-controlled trial demonstrates benefit in IGT. A meta-analysis of T_2DM studies also supports reductions in multiple glycemic and lipid outcomes. These findings are strengthened by mechanistic coherence: *Gymnema constituents can* influence intestinal glucose handling, sweet-taste perception, beta-cell secretion, insulin sensitivity, and cellular stress pathways. [2-13,18]

At the same time, the phrase "*Gymnema works*" is too broad scientifically. Extracts differ chemically, and the mechanisms may not be shared equally by every product. A high-molecular-weight insulin-secretagogue preparation, a GS_4 extract, a gymnemic-acid-rich fraction, a crude leaf powder, and an isolated gymnemic acid preparation are not interchangeable interventions. This heterogeneity is a central reason pooled estimates show high statistical in consistency. [2,3,5,7,13]

4.2 Clinical significance and place in therapy

Current evidence is most compatible with an adjunctive role rather than replacement of established diabetes therapy. This distinction is important because T_2DM management is not limited to lowering glucose; modern treatment choices are also guided by cardiovascular risk, kidney protection, body weight, hypoglycemia risk, and long-term outcome data. *Gymnema studies have* not yet generated comparable cardiovascular- or renal-outcome evidence. [32]

The greatest near-term research opportunity may be early dysglycemia, where lifestyle modification remains foundational and a low-cost plant-derived adjunct could be evaluated for its ability to delay progression to diabetes. The IGT trial provides a proof-of-concept signal, but larger and longer studies with incident diabetes as an endpoint would be needed before preventive claims are justified. [6,32]

4.3 Why the evidence remains heterogeneous

Formulation heterogeneity is likely the dominant source of in consistency. Studies vary in extraction method, concentration, dose, duration, and whether the intervention is a single-herb or multi-herb product. Differences in baseline HbA1c, duration of diabetes, beta-cell reserve, diet, and background medication further modify response. Finally, many early studies predate current standards for trial registration, allocation concealment, blinded outcome assessment, pre defined statistical analysis, and CONSORT reporting. [13-15,17]

Analytical standardization should therefore be considered part of clinical trial methodology, not merely a manufacturing detail. A high-quality trial should report voucher specimen or botanical authentication, extraction solvent and ratio, chromatographic fingerprint, quantitative marker profile, stability, heavy metals, pesticides, microbial testing, and ideally independent batch verification. [19,22,28,31]

4.4 Interpretation of beta-cell "regeneration" claims

Some historical papers inferred beta-cell regeneration or repair from increased insulin/C-peptide and reduced medication requirements. These observations are compatible with improved beta-cell function, reduced glucotoxicity, or enhanced insulin secretion, but they do not directly demonstrate regeneration of beta-cell mass in humans. Contemporary manuscripts should therefore describe such findings as improved endogenous insulin secretory function unless direct regenerative evidence is available. [4,5,25]

4.5 Comparison of clinical and mechanistic evidence

The mechanistic literature is broader and often stronger than the clinical literature in demonstrating target engagement. Intestinal glucose-uptake experiments, human-islet secretion studies, and ER-stress/insulin-signaling studies provide plausible pathways that can explain clinical observations. However, mechanistic plausibility cannot compensate for weak clinical design. Translation depends on whether the same active constituents and exposures are achieved in humans, whether target effects persist chronically, and whether benefits outweigh risks in combination with standard therapy. [5,8-10,18]

4.6 Research priorities

Table 6. Priority areas and recommended approaches for future clinical and translational research on *Gymnema sylvestre* and gymnemic acid.

Priority	Recommended approach
Chemically standardized intervention	Define extract fingerprint and quantitative gymnemic-acid profile; retain reference samples.
Adequately powered RCT	Parallel-group, double-blind, placebo-controlled design with concealed allocation and prospective registration. [17]
Clinically meaningful endpoints	HbA1c at ≥24 weeks, fasting/postprandial glucose, time-in-range where feasible, medication intensification/de-intensification, weight, lipids, patient-reported outcomes.

Priority	Recommended approach
Safety monitoring	Hypoglycemia, hepatic panel, renal function, adverse events, medication interactions, discontinuations.
Subgroup biology	Baseline beta-cell reserve, diabetes duration, concurrent therapy, prediabetes vs established T_2DM.
Pharmacokinetics / exposure biomarkers	Develop biomarkers for active gymnemic-acid species and relate systemic or intestinal exposure to response.
Long-term outcomes	Progression from IGT to T_2DM and, eventually, cardiovascular/renal outcomes if efficacy is confirmed.

5. Strengths and Limitations of This Review

A major strength is the integration of clinical, mechanistic, phytochemical, extraction, and safety evidence rather than treating efficacy as an isolated question. The review also separates direct single-herb evidence from less attributable multi-herb interventions and explicitly avoids using unverified records from the uploaded evidence audit as if they were eligible studies.

The principal limitation is that this reconstruction is not a de novo, prospectively registered PRISMA review with duplicate independent screening of complete database exports. The newly supplied 295-record evidence file improves traceability and source discovery, but it is not yet a completed systematic-review extraction: 294 records were unscreened, none was citation- or full-text-verified, key study-characteristic fields were empty, and risk of bias had not been formally assessed. Consequently, the manuscript deliberately separates dataset audit from evidence synthesis and does not use the software "included" flag as a final eligibility decision. Some older clinical studies remain difficult to retrieve in complete form, and formulation details are inconsistently reported. Accordingly, this review is comprehensive and evidence-informed but should be converted to a formal PRISMA systematic review only after independent screening, full-text verification, structured extraction and risk-of-bias assessment are completed. [17]

6. Conclusion

Gymnema sylvestre and gymnemic-acid-containing preparations have a credible, biologically coherent glucose-lowering signal supported by historical clinical studies, a more recent randomized trial in impaired glucose tolerance, a meta-analysis in T_2DM, and multiple mechanistic models. The evidence suggests effects on postprandial glucose handling, insulin secretion, insulin sensitivity, sweet-taste biology, and cellular stress pathways. Nevertheless, methodological heterogeneity, small sample sizes, limited standardization, and in complete long-term safety data prevent firm conclusions about optimal dose, preparation, or clinical role. At present, Gymnema is best considered a promising adjunctive research candidate rather than a substitute for established diabetes treatment. The next generation of studies should use chemically defined preparations, rigorous randomized designs, clinically meaningful endpoints, and proactive safety and interaction monitoring. [2-4,6,9-13,18,28-30]

Declarations

Author contributions: Muhammad Sanan: Conceptualization, project supervision, methodology, and manuscript preparation. Malaika Afzaal: Data collection, literature review, and manuscript writing. Muhammad Hanan: Data analysis, interpretation of results, and manuscript review. Abdul Ahad: Literature review, data validation, and manuscript editing. Muhammad Sheraz Ahmad: Technical input, literature review, and critical revision of the manuscript. All authors contributed to the development of the manuscript and approved the final version for publication.

Funding: No specific funding was received for this work.

Institutional review board statement: Not applicable. This review examined previously published literature and did not involve new research involving human participants or animals.

Informed consent statement: Not applicable. This review did not involve direct participation of human subjects or the use of identifiable personal information.

Data availability: The published sources supporting this review are cited in the reference list. No new experimental datasets were generated.

Acknowledgements: The authors would like to express their sincere gratitude to their respective institutions for providing the academic support and resources necessary to complete this research. We are thankful to our teachers, mentors, and colleagues for their valuable guidance, encouragement, and constructive feedback throughout the research process. We also acknowledge the support and cooperation of everyone who contributed directly or in directly to this work. Finally, we extend our heartfelt appreciation to our families for their continuous encouragement, patience, and support throughout this research.

Competing interests: The authors declare that they have no financial or non-financial competing interests that could have influenced the research presented in this manuscript.

Use of artificial intelligence tools: If AI-assisted tools were used for language editing, screening support, or manuscript organization, their use should be disclosed according to the target journal's current policy. The authors remain responsible for source verification, interpretation, and the final manuscript.

References

1. American Diabetes Association Professional Practice Committee for Diabetes. 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1): S_{27}-S_{49}. doi: 10.2337/dc26-S_{002}.
2. Tiwari *P*, Mishra BN, Sangwan NS. Phytochemical and pharmacological properties of *Gymnema sylvestre*: an important medicinal plant. Biomed Res Int. 2014;2014:830285. doi: 10.1155/2014/830285.
3. Khan *F*, Sarker MMR, Ming LC, et al. Comprehensive review on phytochemicals, pharmacological and clinical potentials of *Gymnema sylvestre*. Front Pharmacol. 2019;10:1223. doi: 10.3389/fphar.2019.01223.
4. Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram ER. Antidiabetic effect of a leaf extract from *Gymnema sylvestre* in non-insulin-dependent diabetes mellitus patients. J Ethnopharmacol. 1990;30(3):295-300. doi: 10.1016/0378-8741(90)90108-6.
5. Al-Romaiyan A, Liu B, Asare-Anane *H*, et al. A novel *Gymnema sylvestre extract* stimulates insulin secretion from human islets in vivo and in vitro. Phytother Res. 2010;24(9):1370-1376. doi: 10.1002/ptr.3125.
6. Gaytán Martínez LA, Sánchez-Ruiz LA, Zuñiga LY, González-Ortiz M, Martínez-Abundis E. Effect of *Gymnema sylvestre administration* on glycemic control, insulin secretion, and insulin sensitivity in patients with impaired glucose tolerance. J Med Food. 2021;24(1):28-32. doi: 10.1089/jmf.2020.0024.
7. Al-Romaiyan A, King AJ, Persaud SJ, Jones PM. A novel extract of *Gymnema sylvestre improves* glucose tolerance in vivo and stimulates insulin secretion and synthesis in vitro. Phytother Res. 2013;27(7):1006-1011. doi: 10.1002/ptr.4815.
8. Al-Romaiyan A, Liu B, Docherty *R*, et al. Investigation of intracellular signalling cascades mediating stimulatory effect of a *Gymnema sylvestre extract* on insulin secretion from isolated mouse and human islets of Langerhans. Diabetes Obes Metab. 2012;14(12):1104-1113. doi: 10.1111/j.1463-1326.2012.01660.x.
9. Shimizu K, Iino A, Nakajima J, et al. Suppression of glucose absorption by some fractions extracted from *Gymnema sylvestre leaves*. J Vet Med Sci. 1997;59(4):245-251. doi: 10.1292/jvms.59.245.
10. Yoshikawa M, Murakami *T*, Kadoya M, et al. Medicinal foodstuffs. IX. The inhibitors of glucose absorption from the leaves of *Gymnema sylvestre R*. Br.: structures of gymnemosides a and b. Chem Pharm Bull (Tokyo). 1997;45(10):1671-1676. doi: 10.1248/cpb.45.1671.
11. Kurihara Y. Characteristics of antisweet substances, sweet proteins, and sweetness-inducing proteins. Crit Rev Food Sci Nutr. 1992;32(3):231-252. doi: 10.1080/10408399209527598.
12. Maaroufi *H*. Novel gurmarin-like peptides from *Gymnema sylvestre* and their interactions with the sweet taste receptor T_1R_2/T_1R_3. Chem Senses. 2024;49: bjae018. doi: 10.1093/chemse/bjae018.
13. Devangan S, Varghese B, Johny E, Gurram S, Adela *R*. The effect of *Gymnema sylvestre supplementation* on glycemic control in type 2 diabetes patients: a systematic review and meta-analysis. Phytother Res. 2021;35(12):6802-6812. doi: 10.1002/ptr.7265.
14. Leach MJ. *Gymnema sylvestre* for diabetes mellitus: a systematic review. J Altern Complement Med. 2007;13(9):977-983. doi: 10.1089/acm.2006.6387.
15. Ulbricht C, Abrams TR, Basch E, et al. An evidence-based systematic review of gymnema (*Gymnema sylvestre R*. Br.) by the Natural Standard Research Collaboration. J Diet Suppl. 2011;8(3):311-330. doi: 10.3109/19390211.2011.597977.
16. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003;26(4):1277-1294. doi: 10.2337/diacare.26.4.1277.
17. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. doi: 10.1136/bmj.n71.
18. Li Y, Sun M, Liu Y, Liang J, Wang *T*, Zhang *Z*. Gymnemic acid alleviates type 2 diabetes mellitus and suppresses endoplasmic reticulum stress in vivo and in vitro. J Agric Food Chem. 2019;67(13):3662-3669. doi: 10.1021/acs.jafc.9b00431.
19. Kameswaran S, Perumal K. Extraction and purification of gymnemic acid from Gymnema sylvestre R.Br. In: Khasim SM, Long C, Thammasiri K, Lutken H, editors. Medicinal plants: biodiversity, sustainable utilization and conservation. Singapore: Springer; 2020. p. 521–529. doi:10.1007/978-981-15-1636-8_29.
20. Vellai RD, Chandiran S, Sorimuthu Pillai S. GTF-231, a mixture of gymnemic acid, trigonelline and ferulic acid significantly ameliorates oxidative stress in experimental type 2 diabetes in rats. Can J Diabetes. 2018;42(3):237-244. doi: 10.1016/j.jcjd.2017.05.007.
21. Nagella *P*, Dandin VS, Murthy HN. Production of gymnemic acid from cell suspension cultures of *Gymnema sylvestre*. Methods Mol Biol. 2016;1391:229-239. doi: 10.1007/978-1-4939-3332-7_16.
22. Shahzad A, Kausar A, Javed S, Tahseen S, Wasi A. Application of different tissue culture techniques for in vitro production of gymnemic acid: factors, approaches, and challenges to achieve higher yield. In: Kavi Kishor PB, Pullaiah T, Suprasanna P, Ranga Rao A, Romano A, editors. Biotechnological production of bioactive phytochemicals of medicinal value: a comprehensive treatise. Elsevier; 2024. p. 375–389. doi:10.1016/B978-0-443-21818-7.00006-X.
23. Roshana Devi *V*, Sharmila C, Subramanian S. Molecular docking studies involving the inhibitory effect of gymnemic acid, trigonelline and ferulic acid, the phytochemicals with antidiabetic properties, on glycogen synthase kinase 3 (α and β). J Appl Pharm Sci. 2018;8(4):150-160. doi: 10.7324/JAPS.2018.8422.
24. Khare AK, Tondon RN, Tewari JP. Hypoglycaemic activity of an indigenous drug (*Gymnema sylvestre*, "Gurmar") in normal and diabetic persons. Indian J Physiol Pharmacol. 1983;27(3):257-258. PMID: 6668058.
25. Shanmugasundaram ER, Rajeswari G, Baskaran K, Rajesh Kumar BR, Radha Shanmugasundaram K, Kizar Ahmath B. Use of *Gymnema sylvestre leaf* extract in the control of blood glucose in insulin-dependent diabetes mellitus. J Ethnopharmacol. 1990;30(3):281-294. doi: 10.1016/0378-8741(90)90107-5.

26. Kumar SN, Mani UV, Mani I. An open label study on the supplementation of *Gymnema sylvestre* in type 2 diabetics. J Diet Suppl. 2010;7(3):273-282. doi: 10.3109/19390211.2010.505901.

27. Mahajan S, Chauhan *P*, Subramani SK, Anand A, Borole D, Goswamy *H*, et al. Evaluation of "GSPF kwath": a *Gymnema sylvestre-containing polyherbal* formulation for the treatment of human type 2 diabetes mellitus. Eur J Integr Med. 2015;7(3):303-311. doi: 10.1016/j.eujim.2015.01.003.

28. German Federal Institute for Risk Assessment (BfR), Germany; Marakis G, Ziegenhagen *R*, Lampen A, Hirsch-Ernst KI. Risk assessment of substances used in food supplements: the example of the botanical *Gymnema sylvestre*. EFSA J. 2018;16(Suppl 1): e16083. doi: 10.2903/j.efsa.2018.e16083.

29. Shiyovich A, Sztarkier I, Nesher L. Toxic hepatitis induced by *Gymnema sylvestre*, a natural remedy for type 2 diabetes mellitus. Am J Med Sci. 2010;340(6):514-517. doi: 10.1097/MAJ.0b013e3181f41168.

30. Gymnema. In: LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012– [updated 2024 Oct 28; cited 2026 Oct 29]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK610217/.

31. Nagella *P*, Chung IM, Murthy HN. In vitro production of gymnemic acid from cell suspension cultures of *Gymnema sylvestre R*. Br. Eng Life Sci. 2011;11(5):537-540. doi: 10.1002/elsc.201000167.

32. American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1): S_{183}-S_{215}. doi: 10.2337/dc26-S_{009}.